Inovio Pharmaceuticals, Inc. (INO.MX)
| Previous close | 39.00 |
| Open | 0.00 |
| Bid | 38.00 x N/A |
| Ask | 41.80 x N/A |
| Day's range | 39.00 - 39.00 |
| 52-week range | 37.00 - 204.00 |
| Volume | |
| Avg. volume | 348 |
| Market cap | 8.933B |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -30.76 |
| Earnings date | 08 Aug 2022 - 12 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Is This Vaccine Stock in Trouble -- or Ready for a Rebound?
In the early days of the coronavirus vaccine race, Inovio Pharmaceuticals (NASDAQ: INO) was one of the favorites. One major headwind slowed things down: The U.S. Food and Drug Administration (FDA) placed Inovio's coronavirus vaccine trial on a partial clinical hold in late 2020. Does all of this mean Inovio is in trouble?
- Zacks
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Lags Revenue Estimates
Inovio (INO) delivered earnings and revenue surprises of -28.57% and 56.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
INOVIO Reports First Quarter 2022 Financial Results and Program Developments
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today reported financial results for the quarter ended March 31, 2022 and announced recent program and corporate developments. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update.
